Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (DGX) announced that its Senior VP and Chief Human Resources Officer, Cecilia McKenney, received the "CHRO Lifetime Achievement Award" from SharedXpertise Media. Recognized for her leadership during the COVID-19 pandemic, McKenney has championed initiatives promoting employee well-being and inclusion since joining the company in 2018. CEO Steve Rusckowski praised her empathetic leadership style, highlighting her positive impact on the organization. The award celebrates CHROs who drive innovation and excellence in employee engagement and retention, further emphasizing the importance of strong HR leadership in business growth.
Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.66 per share, scheduled for payment on July 20, 2022. Shareholders of record as of July 6, 2022 will receive this dividend. This distribution reflects the company’s commitment to returning value to its investors.
Quest Diagnostics is a leader in diagnostic services, serving one in three adult Americans and half of U.S. physicians and hospitals. Its insights aim to improve health outcomes and healthcare management.
Quest Diagnostics (NYSE: DGX) will present at the UBS 2022 Global Healthcare Conference on May 24, 2022, at 3:30 p.m. ET. CEO Steve Rusckowski and CEO-elect Jim Davis will discuss the company's vision and capital strategies. The event will be available via live webcast on the company's investor relations page and archived for later viewing until June 23, 2022. Quest Diagnostics is a leader in diagnostic information services, supporting health improvements for a significant portion of the U.S. population.
Summary not available.
Quest Diagnostics has introduced a blood test, QUEST AD-Detect™, to assess the risk of Alzheimer's Disease (AD), amidst rising optimism among physicians and patients for advancements in AD diagnostics and treatment. A recent survey showed 66% of physicians anticipate groundbreaking therapies, with 84% believing early risk testing will enhance disease management. However, cost concerns may hinder widespread adoption. Despite this, 87% of physicians think the blood test will become a standard practice, highlighting an evolving landscape in AD healthcare.
Quest Diagnostics (DGX) reported Q1 2022 revenues of $2.61 billion, a 4.0% decline compared to 2021. Reported diluted EPS was $2.92, down 15.6%, while adjusted diluted EPS was $3.22, a drop of 14.4%. Base business revenues rose 6.3% to $2.01 billion. Despite COVID-19 testing revenue decreasing 27.6% to $599 million, full-year guidance was raised. The new diluted EPS guidance ranges from $7.88 to $8.38, with adjusted EPS expected between $9.00 and $9.50.
Quest Diagnostics (NYSE: DGX) announced key organizational changes to enhance operational efficiency and growth. Catherine T. Doherty has been appointed Senior VP for Regional Businesses, while Carrie E. Eglinton Manner takes on Senior VP for Advanced & General Diagnostics Clinical Solutions. Patrick T. Plewman is now Senior VP for Diagnostic Services, and Mark E. Delaney joins as Chief Commercial Officer. Additionally, Richard F. Adams steps in as VP and GM for Consumer Initiated Testing. The company aims to improve strategy execution and strengthen its leadership team.
Quest Diagnostics has announced a collaboration with IRIS to offer diabetic retinal imaging services at its patient service centers across the United States. This initiative aims to enhance access to screenings for diabetic retinopathy, a leading cause of blindness, particularly for patients identified as high-risk by participating health plans. The collaboration is designed to improve screening rates and health outcomes by enabling early detection and treatment. Training for Quest personnel will ensure images are sent to licensed ophthalmologists for evaluation.
Quest Diagnostics (NYSE: DGX) will announce its first quarter 2022 financial results on April 21, 2022, before market opening. A conference call to discuss the results is scheduled at 8:30 a.m. ET. Interested parties can access the call by dialing 888-455-0391 (U.S. and Canada) or 773-756-0467 (international), using the passcode '7895081'. A replay will be available until May 5, 2022. For further information, visit QuestDiagnostics.com/investor.
Quest Diagnostics reported a significant rise in drug test positivity rates in the U.S. workforce, reaching the highest levels since 2001. The overall positivity rate for urine tests increased to 4.6% in 2021, up 31.4% from an all-time low in 2010-2012. Notably, federally mandated safety-sensitive workers' positivity remained steady at 2.2%. Marijuana positivity in the general workforce rose to 3.9%, marking a 50% increase over five years. Employers face challenges in recruitment while ensuring workplace safety amidst these trends.